Inhibiteurs de la monoamine oxydase : Questions médicales fréquentes
Nom anglais: Monoamine Oxidase Inhibitors
Descriptor UI:D008996
Tree Number:D27.505.519.389.616
Termes MeSH sélectionnés :
Quantitative Structure-Activity Relationship
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la monoamine oxydase : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la monoamine oxydase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la monoamine oxydase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-17",
"dateModified": "2025-03-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase",
"alternateName": "Monoamine Oxidase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D008996",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Bijo Mathew",
"url": "https://questionsmedicales.fr/author/Bijo%20Mathew",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682, India."
}
},
{
"@type": "Person",
"name": "Hoon Kim",
"url": "https://questionsmedicales.fr/author/Hoon%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Korea."
}
},
{
"@type": "Person",
"name": "Jacobus P Petzer",
"url": "https://questionsmedicales.fr/author/Jacobus%20P%20Petzer",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa. Electronic address: jacques.petzer@nwu.ac.za."
}
},
{
"@type": "Person",
"name": "Anél Petzer",
"url": "https://questionsmedicales.fr/author/An%C3%A9l%20Petzer",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Chemistry, School of Pharmacy and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa. Electronic address: 12264954@nwu.ac.za."
}
},
{
"@type": "Person",
"name": "Jong Min Oh",
"url": "https://questionsmedicales.fr/author/Jong%20Min%20Oh",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon, Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Leveraging Cell Painting Images to Expand the Applicability Domain and Actively Improve Deep Learning Quantitative Structure-Activity Relationship Models.",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37327474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.chemrestox.2c00404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design, Synthesis, Antibacterial Evaluation, Three-Dimensional Quantitative Structure-Activity Relationship, and Mechanism of Novel Quinazolinone Derivatives.",
"datePublished": "2023-02-21",
"url": "https://questionsmedicales.fr/article/36807581",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jafc.2c07264"
}
},
{
"@type": "ScholarlyArticle",
"name": "Automated machine learning approach for developing a quantitative structure-activity relationship model for cardiac steroid inhibition of Na",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37354314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s43440-023-00508-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multivariate image analysis applied to quantitative structure-activity relationships and docking studies of recent hydroxyphenylpyruvate deoxygenase inhibitors.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37021557",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jsfa.12608"
}
},
{
"@type": "ScholarlyArticle",
"name": "Artificial Intelligence-Based Quantitative Structure-Property Relationship Model for Predicting Human Intestinal Absorption of Compounds with Serotonergic Activity.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37070956",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.molpharmaceut.2c01117"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de la monoamine oxydase",
"item": "https://questionsmedicales.fr/mesh/D008996"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la monoamine oxydase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la monoamine oxydase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la monoamine oxydase",
"description": "Comment diagnostiquer une dépression nécessitant des IMAO ?\nQuels tests sont utilisés pour évaluer l'efficacité des IMAO ?\nLes IMAO sont-ils prescrits pour d'autres troubles ?\nComment évaluer les effets secondaires des IMAO ?\nLes IMAO nécessitent-ils un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la monoamine oxydase",
"description": "Quels symptômes indiquent un besoin d'IMAO ?\nLes IMAO peuvent-ils aggraver certains symptômes ?\nQuels symptômes d'interaction médicamenteuse avec les IMAO ?\nLes IMAO affectent-ils l'appétit ?\nQuels symptômes de sevrage des IMAO ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la monoamine oxydase",
"description": "Comment prévenir les effets secondaires des IMAO ?\nY a-t-il des mesures préventives avant de commencer un IMAO ?\nComment éviter les interactions médicamenteuses avec les IMAO ?\nLes patients doivent-ils être éduqués sur les IMAO ?\nQuelles sont les recommandations alimentaires pour les patients sous IMAO ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la monoamine oxydase",
"description": "Comment fonctionnent les IMAO dans le traitement de la dépression ?\nQuels sont les principaux IMAO disponibles ?\nComment prendre des IMAO en toute sécurité ?\nLes IMAO nécessitent-ils des ajustements de dose ?\nLes IMAO sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la monoamine oxydase",
"description": "Quelles sont les complications possibles des IMAO ?\nComment gérer une crise hypertensive due aux IMAO ?\nLes IMAO peuvent-ils causer des problèmes cardiaques ?\nQuels sont les signes d'une réaction allergique aux IMAO ?\nLes IMAO peuvent-ils interférer avec d'autres traitements ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la monoamine oxydase",
"description": "Quels sont les facteurs de risque pour les effets secondaires des IMAO ?\nLes antécédents familiaux influencent-ils l'utilisation des IMAO ?\nLe mode de vie affecte-t-il l'efficacité des IMAO ?\nLes interactions alimentaires sont-elles un facteur de risque ?\nLes patients ayant des troubles psychiatriques sont-ils à risque ?",
"url": "https://questionsmedicales.fr/mesh/D008996?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dépression nécessitant des IMAO ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est basé sur des critères cliniques, l'historique médical et des évaluations psychologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des IMAO ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles d'évaluation de la dépression et des suivis cliniques réguliers sont utilisés."
}
},
{
"@type": "Question",
"name": "Les IMAO sont-ils prescrits pour d'autres troubles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés pour des troubles anxieux et certains troubles alimentaires."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des IMAO ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des consultations régulières et des questionnaires."
}
},
{
"@type": "Question",
"name": "Les IMAO nécessitent-ils un suivi médical ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'IMAO ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une humeur dépressive persistante, une perte d'intérêt et des troubles du sommeil."
}
},
{
"@type": "Question",
"name": "Les IMAO peuvent-ils aggraver certains symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent aggraver l'anxiété ou provoquer des effets indésirables comme des maux de tête."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'interaction médicamenteuse avec les IMAO ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des palpitations, des maux de tête ou une hypertension peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les IMAO affectent-ils l'appétit ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent provoquer une augmentation ou une diminution de l'appétit chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels symptômes de sevrage des IMAO ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes de sevrage peuvent inclure des vertiges, des nausées et des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des IMAO ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments riches en tyramine et suivre les recommandations médicales aide à prévenir les effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant de commencer un IMAO ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une évaluation complète de l'historique médical et des médicaments en cours est nécessaire."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses avec les IMAO ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer le médecin de tous les médicaments pris et éviter les médicaments non prescrits."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être éduqués sur les IMAO ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des patients sur les IMAO et leurs effets est essentielle pour une utilisation sécurisée."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations alimentaires pour les patients sous IMAO ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments fermentés, les fromages vieillis et les boissons alcoolisées est recommandé."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les IMAO dans le traitement de la dépression ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'enzyme monoamine oxydase, augmentant les niveaux de neurotransmetteurs comme la sérotonine."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux IMAO disponibles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux IMAO incluent la phénelzine, la tranylcypromine et l'isocarboxazide."
}
},
{
"@type": "Question",
"name": "Comment prendre des IMAO en toute sécurité ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial de suivre les instructions du médecin et d'éviter certains aliments et médicaments."
}
},
{
"@type": "Question",
"name": "Les IMAO nécessitent-ils des ajustements de dose ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements peuvent être nécessaires en fonction de la réponse du patient et des effets secondaires."
}
},
{
"@type": "Question",
"name": "Les IMAO sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être efficaces à long terme, mais un suivi régulier est nécessaire pour évaluer leur efficacité."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des IMAO ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'hypertension, les crises hypertensives et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment gérer une crise hypertensive due aux IMAO ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une crise hypertensive nécessite une intervention médicale immédiate et un traitement antihypertenseur."
}
},
{
"@type": "Question",
"name": "Les IMAO peuvent-ils causer des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de problèmes cardiaques, surtout en cas d'interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une réaction allergique aux IMAO ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des éruptions cutanées, des démangeaisons et des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Les IMAO peuvent-ils interférer avec d'autres traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent interférer avec d'autres traitements, nécessitant une évaluation médicale approfondie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les effets secondaires des IMAO ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, des antécédents de maladies cardiaques et d'autres médicaments."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils l'utilisation des IMAO ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dépression ou de troubles mentaux peuvent influencer la décision de traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité des IMAO ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer l'efficacité des IMAO et réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les interactions alimentaires sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la consommation d'aliments riches en tyramine peut augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les patients ayant des troubles psychiatriques sont-ils à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des troubles psychiatriques peuvent avoir un risque accru d'effets secondaires."
}
}
]
}
]
}
The search for chemical hit material is a lengthy and increasingly expensive drug discovery process. To improve it, ligand-based quantitative structure-activity relationship models have been broadly a...
Plant bacterial illnesses are common and cause dramatic damage to agricultural goods all over the world, yet there are few efficient bactericides to alleviate them at present. To discover novel antiba...
Quantitative structure-activity relationship (QSAR) modeling is a method of characterizing the relationship between chemical structures and biological activity. Automated machine learning enables comp...
The chemical structures and inhibitory activities of 215 CS derivatives were obtained from the scientific literature. Predictive QSAR models were constructed using molecular descriptors, fingerprints,...
The best predictive QSAR models were selected based on the LogLoss value. Using these models, the Matthews correlation coefficient, F1 score, and area under the curve of the test dataset were 0.6729, ...
The automated machine learning-based QSAR method developed here should be applicable for the time-efficient construction of predictive models using only a small number of compounds....
Mesotrione is a triketone widely used as an inhibitor of the hydroxyphenylpyruvate deoxygenase (HPPD) enzyme. However, new agrochemicals should be developed continuously to tackle the problem of herbi...
The MIA-QSAR models based on van der Waals radii (r...
Multivariate image analysis descriptors corroborated by docking studies were capable of modeling the herbicidal activities of 68 triketones reliably. Due to the substituent effects at the triketone fr...
Oral medicines represent the largest pharmaceutical market area. To achieve a therapeutic effect, a drug must penetrate the intestinal walls, the main absorption site for orally delivered active pharm...
Organic compounds are capable of generating hydroxyl radicals (˙OH) through their excited triplet states in natural water. It is of significance to reveal the underlying mechanism of the generation an...
Fungal genera Alternaria and Fusarium include human and plant pathogenic species. Several antifungals have been used for their control, but excessive use has contributed to resistance development in p...
To evaluate in vitro and in silico the antifungal activities of terpenoids against Alternaria alternata and Fusarium oxysporum....
The minimum inhibitory concentration and minimum fungicidal concentration values of 27 constituents of essential oils used against Alternaria alternata and Fusarium oxysporum were evaluated in vitro. ...
The evaluated compounds proved to be effective antifungals. Thymol was the most active with a minimum inhibitory concentration of 91.6 ± 28.8 μg/ml for A. alternata and F. oxysporum. Quantitative stru...
Terpenoids exhibit relevant antifungal activities that should be incorporated into the study of medicinal chemistry. Inclusion of in silico assays in the in vitro evaluation is a valuable tool in the ...
Currently, increasing availability and popularity of designer benzodiazepines (DBZDs) constitutes a primary threat to public health. To assess this threat, the biological activity/potency of DBZDs was...
3D-QSAR models were established by collecting 46 multivariate-substituted 4-oxyquinazoline HDAC6 inhibitors. The relationship of molecular structure and inhibitory activity was studied by comparative ...
The leading cause of atherosclerotic cardiovascular disease (ASCVD) is elevated low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) attaches to the domai...